Canada businesses are providing untested stem cell treatment


In an article reviewing the study in BioNews,  Dr Leigh Turner, the researcher and bioethicist at the University of Minnesota, said 'I'm very concerned about the risks associated with businesses making dramatic claims about stem cell treatments for a wide range of diseases and injuries without doing the careful, costly, and time-consuming work needed to develop a compelling evidence base for such representations.'

Most of the companies sold treatments based on autologous stem cells, made from the patient's own cells. The companies sold the treatments as targeting a range of diseases, including neurological conditions, lung diseases, immune conditions and sexual dysfunction. Some also sold treatments for cosmetic procedures.

Clinics charged as much as CA$3,500 (US$2,725) per injection. Many charged smaller additional fees for injections at secondary sites.

Dr Turner has previously studied the market for unproven stem cell treatments in the USA, where there have been more investigations into unlicensed stem cell clinics. In 2017, the FDA launched a crackdown on these clinics.

However, the marketplace for unproven and unlicensed stem cell treatments has not received significant national attention in Canada, Dr Turner said.

For further IMTJ analysis and global news in this sector, visit Stem Cell Treatment.



Do you have some news or a press release that you’d like to share with the medical travel industry?

Publish for FREE on IMTJ.


Related News

Inbound travel to Hong Kong

01 May, 2020

Hong Kong open in July, for Chinese tourists

Improving European cross-border healthcare

24 April, 2020

Ensuring timely access to advanced therapies in Europe

Costa Rica promotes stem cell treatment

23 October, 2019

Costa Rica looks to be stem cell treatment destination

Promoting stem cell treatment

18 October, 2019

Google bans ads for ‘unproven’ stem call treatment

Five global healthcare revolutions

26 September, 2019

Report predicts what will transform healthcare by 2040